Far Eastern Memorial Hospital signs clinical trial cooperation memorandum with AZ in Taiwan

        Every clinical trial is a big step forward in medicine and may even become a turning point in a patient's life. Adhering to the core concept of "patient-centered", Far Eastern Memorial Hospital is not only committed to promoting clinical research, but also actively helping patients to have early access to the latest international drugs and treatment methods, reducing the pain caused by diseases. On August 22nd, Far Eastern Memorial Hospital and AstraZeneca Taiwan (hereinafter referred to as AZ Taiwan) officially signed a memorandum of understanding (MOU) for clinical trial cooperation, working together to accelerate new drug development, improve medical care quality, and promote Taiwan's integration with international healthcare.

        Clinical research advantages, internationally recognized and affirmed

        Far Eastern Memorial Hospital has been deeply involved in clinical research for a long time. Not only do all trials strictly follow international standards, but they will also be fully certified by the American Association for the Protection of Human Research (AAHRPP) in 2025, receiving high international recognition. This is not only a demonstration of professional strength, but also represents the hospital's commitment to patient safety and ethical protection.

        Zhang Zhihong, Vice President of Research, pointed out that Far Eastern Memorial Hospital, with its large patient base and diverse clinical cases, is able to complete the recruitment of subjects in a short period of time, ensuring that the research results are representative and clinically valuable. It has become one of the most trusted partners for international pharmaceutical companies, and can confidently deliver clinical trials to the hospital for execution, accelerating the pace of new drug development and allowing Taiwan to continue to be seen in the global clinical research landscape.

        He also shared that Far Eastern Memorial Hospital has collaborated with AZ in Taiwan on multiple major research projects, covering high impact areas such as cardiovascular disease, chronic kidney disease, non-small cell lung cancer, endometrial cancer, and proliferative lupus nephritis, all of which have clinical value. The signing of this MOU will bring more international opportunities for clinical trials of new drugs to Taiwan, not only increasing research capacity, but also enabling patients to benefit from the latest therapies in advance and shortening the distance with international medical care.

        Far Eastern Memorial Hospital implements patient welfare and creates a friendly experimental field

        Dr. Wu Yanwen, the head of the Medical Research Department at Far Eastern Memorial Hospital, stated that clinical trials are not just about data and processes, but a journey of life that patients and medical teams walk hand in hand. In order to make research more closely aligned with patient needs, Far Eastern Memorial Hospital has developed a cross departmental integrated research support system to assist trial leaders in efficient execution while balancing professionalism and humanity. In addition, the hospital continues to optimize subject recruitment and quality management, create a safe and friendly environment, and actively care for vulnerable groups to ensure that more patients have early access to new drugs and therapies.

        Clinical research is not just about advancing medicine, but also about practicing social responsibility. "Minister Wu Yanwen emphasized that Far Eastern Memorial Hospital always puts" patient's hope "first, ensuring that research results are implemented for patient well-being, reducing the pain caused by diseases, and injecting momentum into social health and global medical development.

        Cai Wanquan, Section Chief of the Clinical Trial Center, added that Far Eastern Memorial Hospital has gradually established a subject protection mechanism since five years ago. This year, it participated in the first international authoritative evaluation in the United States and was fully certified, fully affirming the research quality and patient safety. In the future, hospitals will continue to provide education, training, and community health education to help the public have a correct understanding of clinical trials, emphasizing that their core lies in ensuring safety and building trust. At the same time, the hospital has established a "Subject Protection Center" and a "Clinical Trial Management Center", and works closely with the IRB to ensure that the research team has real-time access to the status of the subjects and comprehensively protects patient safety through supervision and systematic management.

        AZ platform helps open up new hope for treatment

        The President of AZ Taiwan, Jian Shaoting, stated that by signing a memorandum of cooperation on clinical trials, AZ has invited top medical centers in Taiwan to join the PiC (Partner in Care) Network (AZ Joint Healthcare Alliance), participate in early drug development discussions, and speak up for Taiwanese patients. Since 2012, AZ Taiwan has established close clinical trial cooperation with Far Eastern Memorial Hospital, which is one of the top ten medical centers in terms of clinical trial cooperation. Far Eastern Memorial Hospital has helped over 170 patients receive better treatment. In addition, Far Eastern Memorial Hospital has expertise in core areas such as cardiovascular, cancer, critical care, organ transplantation, trauma treatment, minimally invasive surgery, and nephrology, which is highly aligned with AZ's strategy of launching 20 new drugs by 2030.

        Far Eastern Memorial Hospital collaborates to create a new era in healthcare

        Vice President Zhang Zhihong stated that promoting clinical research is not only a breakthrough in medical technology, but also a commitment to the health and life of every patient. The signing of the MOU with AZ Taiwan not only allows Far Eastern Memorial Hospital to continue to speak out on the global clinical trial stage, but also demonstrates the hospital's determination to continue patient life through professional research, rigorous ethics, and profound social responsibility. Every collaboration opens up new hope for patients and enables cutting-edge medical achievements to be implemented in Taiwan.

        #